A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors

Zhaojun Sun, Bernard Lethé, Yi Zhang, Vincenzo Russo, Didier Colau, Vincent Stroobant, Thierry Boon, Pierre Van Der Bruggen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Antigens encoded by genes of the LAGE family, including LAGE-1 and NY-ESO-1, are of interest for cancer immunotherapy because they are tumor-specific and shared by tumors of different histological types. Several clinical trials are in progress with NY-ESO-1 peptides, protein, recombinant poxviruses, and dendritic cells pulsed with peptides. In this study, CD8 T lymphocytes from an individual without cancer were stimulated with dendritic cells infected with a recombinant avian poxvirus encoding a complete LAGE-1 protein. A CTL clone was isolated that recognized a new LAGE-1 peptide, ELVRRILSR, which corresponds to position 103-111 of the protein sequence. It is presented by HLA-A6801 molecules. When tumor cells expressing LAGE-1 were transfected with HLA-A68, they were lysed by the CTL clone, indicating that the peptide is processed in tumor cells. These results indicate that the LAGE-1.A68 peptide can be used for antitumoral vaccination. We observed also that specific T cells could be detected in a blood sample with a high sensitivity by using an A68/LAGE-1 fluorescent multimer.

Original languageEnglish
Pages (from-to)644-652
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume55
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

T-Lymphocytes
Peptides
Poxviridae
Neoplasms
Dendritic Cells
Clone Cells
Recombinant Proteins
Immunotherapy
Vaccination
Proteins
Clinical Trials
Antigens
Genes

Keywords

  • HLA-A68
  • LAGE-1
  • Peptide
  • Poxvirus
  • SNP
  • Tumor

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Sun, Z., Lethé, B., Zhang, Y., Russo, V., Colau, D., Stroobant, V., ... Van Der Bruggen, P. (2006). A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunology, Immunotherapy, 55(6), 644-652. https://doi.org/10.1007/s00262-005-0066-x

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. / Sun, Zhaojun; Lethé, Bernard; Zhang, Yi; Russo, Vincenzo; Colau, Didier; Stroobant, Vincent; Boon, Thierry; Van Der Bruggen, Pierre.

In: Cancer Immunology, Immunotherapy, Vol. 55, No. 6, 06.2006, p. 644-652.

Research output: Contribution to journalArticle

Sun, Z, Lethé, B, Zhang, Y, Russo, V, Colau, D, Stroobant, V, Boon, T & Van Der Bruggen, P 2006, 'A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors', Cancer Immunology, Immunotherapy, vol. 55, no. 6, pp. 644-652. https://doi.org/10.1007/s00262-005-0066-x
Sun, Zhaojun ; Lethé, Bernard ; Zhang, Yi ; Russo, Vincenzo ; Colau, Didier ; Stroobant, Vincent ; Boon, Thierry ; Van Der Bruggen, Pierre. / A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. In: Cancer Immunology, Immunotherapy. 2006 ; Vol. 55, No. 6. pp. 644-652.
@article{c3054076de0344c085699732c433120a,
title = "A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors",
abstract = "Antigens encoded by genes of the LAGE family, including LAGE-1 and NY-ESO-1, are of interest for cancer immunotherapy because they are tumor-specific and shared by tumors of different histological types. Several clinical trials are in progress with NY-ESO-1 peptides, protein, recombinant poxviruses, and dendritic cells pulsed with peptides. In this study, CD8 T lymphocytes from an individual without cancer were stimulated with dendritic cells infected with a recombinant avian poxvirus encoding a complete LAGE-1 protein. A CTL clone was isolated that recognized a new LAGE-1 peptide, ELVRRILSR, which corresponds to position 103-111 of the protein sequence. It is presented by HLA-A6801 molecules. When tumor cells expressing LAGE-1 were transfected with HLA-A68, they were lysed by the CTL clone, indicating that the peptide is processed in tumor cells. These results indicate that the LAGE-1.A68 peptide can be used for antitumoral vaccination. We observed also that specific T cells could be detected in a blood sample with a high sensitivity by using an A68/LAGE-1 fluorescent multimer.",
keywords = "HLA-A68, LAGE-1, Peptide, Poxvirus, SNP, Tumor",
author = "Zhaojun Sun and Bernard Leth{\'e} and Yi Zhang and Vincenzo Russo and Didier Colau and Vincent Stroobant and Thierry Boon and {Van Der Bruggen}, Pierre",
year = "2006",
month = "6",
doi = "10.1007/s00262-005-0066-x",
language = "English",
volume = "55",
pages = "644--652",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",

}

TY - JOUR

T1 - A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors

AU - Sun, Zhaojun

AU - Lethé, Bernard

AU - Zhang, Yi

AU - Russo, Vincenzo

AU - Colau, Didier

AU - Stroobant, Vincent

AU - Boon, Thierry

AU - Van Der Bruggen, Pierre

PY - 2006/6

Y1 - 2006/6

N2 - Antigens encoded by genes of the LAGE family, including LAGE-1 and NY-ESO-1, are of interest for cancer immunotherapy because they are tumor-specific and shared by tumors of different histological types. Several clinical trials are in progress with NY-ESO-1 peptides, protein, recombinant poxviruses, and dendritic cells pulsed with peptides. In this study, CD8 T lymphocytes from an individual without cancer were stimulated with dendritic cells infected with a recombinant avian poxvirus encoding a complete LAGE-1 protein. A CTL clone was isolated that recognized a new LAGE-1 peptide, ELVRRILSR, which corresponds to position 103-111 of the protein sequence. It is presented by HLA-A6801 molecules. When tumor cells expressing LAGE-1 were transfected with HLA-A68, they were lysed by the CTL clone, indicating that the peptide is processed in tumor cells. These results indicate that the LAGE-1.A68 peptide can be used for antitumoral vaccination. We observed also that specific T cells could be detected in a blood sample with a high sensitivity by using an A68/LAGE-1 fluorescent multimer.

AB - Antigens encoded by genes of the LAGE family, including LAGE-1 and NY-ESO-1, are of interest for cancer immunotherapy because they are tumor-specific and shared by tumors of different histological types. Several clinical trials are in progress with NY-ESO-1 peptides, protein, recombinant poxviruses, and dendritic cells pulsed with peptides. In this study, CD8 T lymphocytes from an individual without cancer were stimulated with dendritic cells infected with a recombinant avian poxvirus encoding a complete LAGE-1 protein. A CTL clone was isolated that recognized a new LAGE-1 peptide, ELVRRILSR, which corresponds to position 103-111 of the protein sequence. It is presented by HLA-A6801 molecules. When tumor cells expressing LAGE-1 were transfected with HLA-A68, they were lysed by the CTL clone, indicating that the peptide is processed in tumor cells. These results indicate that the LAGE-1.A68 peptide can be used for antitumoral vaccination. We observed also that specific T cells could be detected in a blood sample with a high sensitivity by using an A68/LAGE-1 fluorescent multimer.

KW - HLA-A68

KW - LAGE-1

KW - Peptide

KW - Poxvirus

KW - SNP

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=33644589047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644589047&partnerID=8YFLogxK

U2 - 10.1007/s00262-005-0066-x

DO - 10.1007/s00262-005-0066-x

M3 - Article

C2 - 16187088

AN - SCOPUS:33644589047

VL - 55

SP - 644

EP - 652

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 6

ER -